Your request to link to rcsb for HIV-1 protease M2

---

• 1RPI: crystal structures of a multidrug-resistant hiv-1 protease reveal an expanded active site cavity (10.1128/JVI.78.6.3123-3132.2004 )
• 1RQ9: crystal structures of a multidrug-resistant hiv-1 protease reveal an expanded active site cavity (10.1128/JVI.78.6.3123-3132.2004 )
• 1RV7: crystal structures of a multidrug-resistant hiv-1 protease reveal an expanded active site cavity (10.1128/JVI.78.6.3123-3132.2004 )
• 1TW7: wide open 1.3a structure of a multi-drug resistant hiv-1 protease represents a novel drug target (10.1016/J.STR.2005.11.005 )
• 2F3K: substrate envelope and drug resistance: crystal structure of r01 in complex with wild-type hiv-1 protease (10.1128/AAC.50.4.1518-1521.2006 )
• 2FDD: crystal structure of hiv protease d545701 bound with gw0385 (10.1016/J.BMCL.2006.01.035 )
• 2I0A: crystal structure of kb-19 complexed with wild type hiv-1 protease (10.1021/JM060666P )
• 2I0D: crystal structure of ad-81 complexed with wild type hiv-1 protease (10.1021/JM060666P )
• 2P3C: crystal structure of the subtype f wild type hiv protease complexed with tl-3 inhibitor (10.1016/J.JMB.2007.03.049 )
• 2PSU: crystal structure of wild type hiv-1 protease in complex with carb- ad37 (10.1111/J.1747-0285.2007.00514.X )
• 2PSV: crystal structure of wild type hiv-1 protease in complex with carb- kb45 (10.1111/J.1747-0285.2007.00514.X )
• 2Q3K: crystal structure of lysine sulfonamide inhibitor reveals the displacement of the conserved flap water molecule in hiv-1 protease (10.1128/JVI.00799-07 )
• 2Q54: crystal structure of kb73 bound to hiv-1 protease (10.1021/JM070284Z )
• 2Q55: crystal structure of kk44 bound to hiv-1 protease (10.1021/JM070284Z )
• 2Q5K: crystal structure of lopinavir bound to wild type hiv-1 protease (10.1021/JM070284Z )
• 2QHY: crystal structure of protease inhibitor, mit-1-ac86 in complex with wild type hiv-1 protease (10.1021/JA076558P )
• 2QHZ: crystal structure of protease inhibitor, mit-1-ac87 in complex with wild type hiv-1 protease (10.1021/JA076558P )
• 2QI0: crystal structure of protease inhibitor, mit-1-kk80 in complex with wild type hiv-1 protease (10.1021/JA076558P )
• 2QI1: crystal structure of protease inhibitor, mit-1-kk81 in complex with wild type hiv-1 protease (10.1021/JA076558P )
• 2QI3: crystal structure of protease inhibitor, mit-2-ad94 in complex with wild type hiv-1 protease (10.1021/JA076558P )
• 2QI4: crystal structure of protease inhibitor, mit-2-ad93 in complex with wild type hiv-1 protease (10.1021/JA076558P )
• 2QI5: crystal structure of protease inhibitor, mit-2-kc08 in complex with wild type hiv-1 protease (10.1021/JA076558P )
• 2QI6: crystal structure of protease inhibitor, mit-2-kb98 in complex with wild type hiv-1 protease (10.1021/JA076558P )
• 2QI7: crystal structure of protease inhibitor, mit-2-ad86 in complex with wild type hiv-1 protease (10.1021/JA076558P )
• 3D3T: crystal structure of hiv-1 crf01_ae in complex with the substrate p1- p6 (10.1128/JVI.00018-08 )
• 3EKV: crystal structure of the wild type hiv-1 protease with the inhibitor, amprenavir (10.1021/CB300191K )
• 3EKX: crystal structure of the wild-type hiv-1 protease with the inhibitor, nelfinavir (10.1021/CB300191K )
• 3EKY: crystal structure of wild-type hiv protease in complex with the inhibitor, atazanavir (10.1021/CB300191K )
• 3EM3: crystal structure of amprenavir (apv) in complex with a drug resistant hiv-1 protease variant (i50l/a71v).
• 3GI4: crystal structure of protease inhibitor, kb60 in complex with wild type hiv-1 protease (10.1128/JVI.02531-09 )
• 3GI5: crystal structure of protease inhibitor, kb62 in complex with wild type hiv-1 protease (10.1128/JVI.02531-09 )
• 3GI6: crystal structure of protease inhibitor, ad78 in complex with wild type hiv-1 protease (10.1128/JVI.02531-09 )
• 3IXO: crystal structure of uncomplexed hiv_1 protease subtype a (10.1107/S0907444909054298 )
• 3LZS: crystal structure of hiv-1 crf01_ae protease in complex with darunavir (10.1128/JVI.00505-10 )
• 3LZU: crystal structure of a nelfinavir resistant hiv-1 crf01_ae protease variant (n88s) in complex with the protease inhibitor darunavir. (10.1128/JVI.00505-10 )
• 3MXD: crystal structure of hiv-1 protease inhibitor kc53 in complex with wild-type protease (10.1021/JM1008743 )
• 3MXE: crystal structure of hiv-1 protease inhibitor, kc32 complexed with wild-type protease (10.1021/JM1008743 )
• 3O99: crystal structure of wild-type hiv-1 protease in complex with kd13 (10.1016/J.CHEMBIOL.2013.07.014 )
• 3O9A: crystal structure of wild-type hiv-1 protease in complex with kd14 (10.1016/J.CHEMBIOL.2013.07.014 )
• 3O9B: crystal structure of wild-type hiv-1 protease in complex with kd25 (10.1016/J.CHEMBIOL.2013.07.014 )
• 3O9C: crystal structure of wild-type hiv-1 protease in complex with kd20 (10.1016/J.CHEMBIOL.2013.07.014 )
• 3O9D: crystal structure of wild-type hiv-1 protease in complex with kd19 (10.1016/J.CHEMBIOL.2013.07.014 )
• 3O9E: crystal structure of wild-type hiv-1 protease in complex with af60 (10.1016/J.CHEMBIOL.2013.07.014 )
• 3O9F: crystal structure of wild-type hiv-1 protease in complex with kd27 (10.1016/J.CHEMBIOL.2013.07.014 )
• 3O9G: crystal structure of wild-type hiv-1 protease in complex with af53 (10.1016/J.CHEMBIOL.2013.07.014 )
• 3O9H: crystal structure of wild-type hiv-1 protease in complex with kd26 (10.1016/J.CHEMBIOL.2013.07.014 )
• 3O9I: crystal structure of wild-type hiv-1 protease in complex with af61 (10.1016/J.CHEMBIOL.2013.07.014 )
• 3OQ7: crystal structures of multidrug-resistant clinical isolate 769 hiv-1 protease variants (10.1107/S0907444911011541 )
• 3OQA: crystal structures of multidrug-resistant clinical isolate 769 hiv-1 protease variants (10.1107/S0907444911011541 )
• 3OQD: crystal structures of multidrug-resistant clinical isolate 769 hiv-1 protease variants (10.1107/S0907444911011541 )
• 3OTS: mdr769 hiv-1 protease complexed with ma/ca hepta-peptide (10.1007/S10930-011-9316-2 )
• 3OTY: mdr769 hiv-1 protease complexed with rt/rh hepta-peptide (10.1007/S10930-011-9316-2 )
• 3OU1: mdr769 hiv-1 protease complexed with rh/in hepta-peptide (10.1007/S10930-011-9316-2 )
• 3OU3: mdr769 hiv-1 protease complexed with pr/rt hepta-peptide (10.1007/S10930-011-9316-2 )
• 3OU4: mdr769 hiv-1 protease complexed with tf/pr hepta-peptide (10.1007/S10930-011-9316-2 )
• 3OUA: mdr769 hiv-1 protease complexed with p1/p6 hepta-peptide (10.1007/S10930-011-9316-2 )
• 3OUB: mdr769 hiv-1 protease complexed with nc/p1 hepta-peptide (10.1007/S10930-011-9316-2 )
• 3OUC: mdr769 hiv-1 protease complexed with p2/nc hepta-peptide (10.1007/S10930-011-9316-2 )
• 3OUD: mdr769 hiv-1 protease complexed with ca/p2 hepta-peptide (10.1007/S10930-011-9316-2 )
• 3OXV: crystal structure of hiv-1 i50v, a71 protease in complex with the protease inhibitor amprenavir. (10.1128/JVI.03486-12 )
• 3R0W: crystal structures of multidrug-resistant hiv-1 protease in complex with mechanism-based aspartyl protease inhibitors. (10.1016/J.BBRC.2012.03.096 )
• 3R0Y: crystal structures of multidrug-resistant hiv-1 protease in complex with mechanism-based aspartyl protease inhibitors (10.1016/J.BBRC.2012.03.096 )
• 3R4B: crystal structure of wild-type hiv-1 protease in complex with tmc310911 (10.1128/AAC.00748-11 )
• 3SA3: crystal structure of wild-type hiv-1 protease in complex with ag23
• 3SA4: crystal structure of wild-type hiv-1 protease in complex with af72
• 3SA5: crystal structure of wild-type hiv-1 protease in complex with af69
• 3SA6: crystal structure of wild-type hiv-1 protease in complex with af71
• 3SA7: crystal structure of wild-type hiv-1 protease in complex with af55
• 3SA8: crystal structure of wild-type hiv-1 protease in complex with kb83
• 3SA9: crystal structure of wild-type hiv-1 protease in complex with af68
• 3SAA: crystal structure of wild-type hiv-1 protease in complex with af77
• 3SAB: crystal structure of wild-type hiv-1 protease in complex with af78
• 3SAC: crystal structure of wild-type hiv-1 protease in complex with af80
• 3SO9: darunavir in complex with a human immunodeficiency virus type 1 protease variant (10.1016/J.BBRC.2011.08.045 )
• 3SPK: tipranavir in complex with a human immunodeficiency virus type 1 protease variant (10.1016/J.BBRC.2011.08.045 )
• 4DJO: crystal structure of wild-type hiv-1 protease in complex with mkp56 (10.1021/JM300238H )
• 4DJP: crystal structure of wild-type hiv-1 protease in complex with mkp73 (10.1021/JM300238H )
• 4DJQ: crystal structure of wild-type hiv-1 protease in complex with mkp86 (10.1021/JM300238H )
• 4DJR: crystal structure of wild-type hiv-1 protease in complex with mkp97 (10.1021/JM300238H )
• 4EYR: crystal structure of multidrug-resistant clinical isolate 769 hiv-1 protease in complex with ritonavir (10.1016/J.BBRC.2012.12.127 )
• 4FAE: substrate p2/nc in complex with a human immunodeficiency virus type 1 protease variant
• 4FAF: substrate ca/p2 in complex with a human immunodeficiency virus type 1 protease variant
• 4GYE: mdr 769 hiv-1 protease in complex with reduced p1f (10.1016/J.BMC.2013.09.045 )
• 4GZF: multi-drug resistant hiv-1 protease 769 variant with reduced lrf peptide (10.1016/J.BMC.2013.09.045 )
• 4L1A: crystallographic study of multi-drug resistant hiv-1 protease lopinavir complex: mechanism of drug recognition and resistance (10.1016/J.BBRC.2013.06.027 )
• 4Q1W: mutations outside the active site of hiv-1 protease alter enzyme structure and dynamic ensemble of the active site to confer drug resistance (10.1021/JA504096M )
• 6OOS: hiv-1 protease nl4-3 l90m mutant in complex with darunavir (10.1021/ACS.BIOCHEM.9B00446 )
• 6OOT: hiv-1 protease nl4-3 l89v, l90m mutant in complex with darunavir (10.1021/ACS.BIOCHEM.9B00446 )